Rapport Therapeutics (NASDAQ:RAPP) CEO Abraham Ceesay Sells 1,147 Shares of Company Stock

Posted by Danessa Lincoln on Oct 9th, 2026

Rapport Therapeutics, Inc. (NASDAQ:RAPP – Get Free Report) CEO Abraham Ceesay sold 1,147 shares of the company’s stock in a transaction on Wednesday, October 7th. The stock was sold at an average price of $30.66, for a total transaction of $35,167.02. Following the completion of the transaction, the chief executive officer owned 452,245 shares of the company’s stock, valued at $13,865,831.70. This trade represents a 0.25% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website.

Abraham Ceesay also recently made the following trade(s):

On Tuesday, October 6th, Abraham Ceesay sold 3,375 shares of Rapport Therapeutics stock. The shares were sold at an average price of $32.03, for a total transaction of $108,101.25.
On Wednesday, September 23rd, Abraham Ceesay sold 2,210 shares of Rapport Therapeutics stock. The shares were sold at an average price of $39.17, for a total transaction of $86,565.70.
On Tuesday, September 8th, Abraham Ceesay sold 8,210 shares of Rapport Therapeutics stock. The stock was sold at an average price of $45.61, for a total transaction of $374,458.10.
On Tuesday, August 25th, Abraham Ceesay sold 18,921 shares of Rapport Therapeutics stock. The stock was sold at an average price of $49.57, for a total transaction of $937,913.97.
On Tuesday, August 11th, Abraham Ceesay sold 28,958 shares of Rapport Therapeutics stock. The stock was sold at an average price of $48.01, for a total transaction of $1,390,273.58.
On Monday, August 10th, Abraham Ceesay sold 22,541 shares of Rapport Therapeutics stock. The shares were sold at an average price of $46.26, for a total value of $1,042,746.66.
On Monday, July 27th, Abraham Ceesay sold 2,210 shares of Rapport Therapeutics stock. The stock was sold at an average price of $42.11, for a total value of $93,063.10.

Rapport Therapeutics Stock Performance

Shares of NASDAQ:RAPP opened at $29.85 on Friday. The firm has a market capitalization of $1.43 billion, a P/E ratio of -9.82 and a beta of 1.22. The stock has a 50 day moving average price of $42.73 and a 200-day moving average price of $39.12. Rapport Therapeutics, Inc. has a 52-week low of $23.75 and a 52-week high of $52.93.

Rapport Therapeutics (NASDAQ:RAPP – Get Free Report) last released its quarterly earnings results on Wednesday, August 5th. The company reported ($1.19) earnings per share for the quarter, missing the consensus estimate of ($1.12) by ($0.07). On average, equities analysts forecast that Rapport Therapeutics, Inc. will post -4.09 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several brokerages recently issued reports on RAPP. William Blair assumed coverage on shares of Rapport Therapeutics in a research note on Tuesday, July 28th. They issued an “outperform” rating for the company. UBS Group set a $80.00 price objective on shares of Rapport Therapeutics in a research note on Wednesday, September 23rd. Weiss Ratings restated a “sell (d-)” rating on shares of Rapport Therapeutics in a report on Friday, July 17th. BTIG Research raised their target price on shares of Rapport Therapeutics from $65.00 to $75.00 and gave the company a “buy” rating in a research note on Wednesday, September 16th. Finally, HC Wainwright lifted their target price on shares of Rapport Therapeutics from $40.00 to $66.00 and gave the company a “buy” rating in a report on Wednesday, August 12th. Two equities research analysts have rated the stock with a Strong Buy rating, eleven have assigned a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, Rapport Therapeutics has a consensus rating of “Buy” and an average target price of $66.11.

Check Out Our Latest Report on RAPP

Hedge Funds Weigh In On Rapport Therapeutics

Several institutional investors and hedge funds have recently modified their holdings of the stock. TRV GP V LLC purchased a new position in shares of Rapport Therapeutics in the 2nd quarter worth about $261,709,477. ARCH Venture Management LLC purchased a new stake in Rapport Therapeutics during the 2nd quarter valued at about $155,376,512. BlackRock Inc. purchased a new stake in Rapport Therapeutics during the 2nd quarter valued at about $112,500,000. Goldman Sachs Group Inc. increased its stake in Rapport Therapeutics by 23.9% during the 4th quarter. Goldman Sachs Group Inc. now owns 3,001,879 shares of the company’s stock valued at $91,077,000 after purchasing an additional 579,903 shares in the last quarter. Finally, Johnson & Johnson bought a new stake in Rapport Therapeutics during the 2nd quarter valued at about $74,360,823.

Rapport Therapeutics Company Profile

(Get Free Report)

Rapport Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing medicines for neurological and psychiatric disorders. The company uses its proprietary RAP platform to identify and target synaptic receptor-associated proteins, which can influence the activity, distribution and function of receptors involved in the central nervous system.

Rapport’s lead clinical program is relutrigine, also known as RAP-219, an orally administered small-molecule therapy being developed for focal epilepsy.